摘要
紫癜性肾炎(HSPN)是过敏性紫癜全身性血管炎在肾脏的病理表现,为免疫复合物介导的肾小球损伤,大部分患儿症状不重,仅表现为镜下血尿或微量蛋白尿,有少部分患儿会进展为肾功能不全。目前国际上尚无统一的治疗方案,但一致认为早诊断、早治疗对预后意义重大,尤其对于蛋白尿不转阴的患儿更应积极治疗。国内外对HSPN的诊断标准明确,无论临床分型还是病理分级均有较为一致的参考指标,但对于疾病治疗方面的报道却以回顾性总结及经验治疗为主,药物种类多样,治疗效果缺乏循证医学证据支持,有待大样本多中心的临床研究来指导和规范HSPN的治疗。
Henoch-Schnleinpurpura nephritis（ HSPN） is a pathological manifestation of systemic vasculitis in the kidney,a glomerular injury triggered by the deposited immune complexes. Most patients only have mild symptoms,showing microscopic hematuria or microalbuminuria,but a small percentage of patients present with nephrotic syndrome or renal failure. Although,there is no unified treatment in the world now,early diagnosis and treatment have great significance to the prognosis,especially for children with proteinuria. The diagnostic standard of HSPN is clear,both clinical classification and pathological classification have consistent reference indicators,but the reports on the treatment are mainly retrospective summary and empirical treatment,with various drugs,still lacking evidence-based medicine support for the efficacy of treatment,needing multi-center clinical research to guide and standardize the treatment of HSPN.
作者
郭婷
凌继祖
李宇宁
GUO Ting;LING Jizu;LI Yuning(Department of Pediatrics,the First Hospital of Lanzhou University,Lanzhou 730000,China)
出处
《医学综述》
2018年第15期3001-3006,3012,共7页
Medical Recapitulate
基金
甘肃省卫生行业科研计划项目(GSWSKY-2015-43)
关键词
紫癜性肾炎
儿童
血管紧张素转换酶抑制剂
血管紧张素受体拮抗剂
糖皮质激素
免疫抑制剂
抗凝剂
Henoch-SchoSnleinpurpura nephritis
Child
Angiotensin Ⅱ converting enzyme inhibitors
Angiotensinreceptor antagonist
Glucocorticoid
Inmmnosuppressor
Anticoagulant
